Clinical trial · Observational
Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp
NCT05638542CI-TRIAL-00109354active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study of carcinogenesis-related molecular markers in the patients with colorectal cancer and colorectal adenoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Adenoma | Colorectal Adenoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Control group
- description
- Patients who are not diagnosed with colorectal adenoma or colorectal cancer
- label
- Colorectal adenoma group
- description
- Patients who are diagnosed with colorectal adenoma
- label
- Colorectal cancer group
- description
- Patients who are diagnosed with colorectal cancer
Primary outcomes (2)
- measure
- The characteristics of carcinogenesis-related molecular markers in colorectal adenoma and CRC
- timeFrame
- through study completion, an average of 1 year
- description
- Using endoscopically biopsied specimens, multiple carcinogenic markers were investigated including KRAS and BRAF mutation, PD-L1, EGFR, IL-1b, NLRP3, Caspase-1, p53 expression, Microinstability (MSS, MSI-L, MSI-H), PD-L1, DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), CIMP markers (p16, MINT1, MINT2, MINT31, hMLH1), promoter methylation of p16, RUNX3, NEUROG1. CIMP was assessed by methylation-specific PCR for five methylation panel markers (p16, MINT1, MINT2, MINT31, hMLH1), and MSI status was validated by PCR using five NCI markers (BAT-26, BAT-25, D5S346, D17S250, and S2S123). KRAS and BRAF mutation was analyzed by direct sequencing using sequence-specific primers from the acquired biopsy specimens. PD-L1, EGFR, MMR expression was examined using immunohistochemistry.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Control group: subjects with no evidence of colorectal adenoma or colorectal cancer * Colorectal adenoma group: Patients with colorectal adenomas greater than or equal to 10 mm in diameter according to the endoscopic presentation as well as histological validation of colorectal adenoma. * Colorectal cancer group: Patients whose biopsy specimen is histologically confirmed as colorectal adenocarcinoma Exclusion Criteria: * Subjects age under 18 years * Previous history of colorectal neoplasms * Patients with high bleeding risk or patients who must maintain anti-coagulant or anti-platelet agents * Denial to participate in this study
References
Publications (2)
- DERIVEDChoi Y, Kim N, Song CH, Oh HJ. Sex Hormone Receptor Profiling Reveals an Association between Estrogen Receptor beta-NRF2 Signaling and Improved Outcomes in Colorectal Cancer Patients. Gut Liver. 2026 Jul 24. doi: 10.5009/gnl250538. Online ahead of print. PMID 42494363
- DERIVEDChoi J, Kim N, Nam RH, Kim JW, Song CH, Na HY, Kang GH. Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis. PLoS One. 2023 Feb 21;18(2):e0282017. doi: 10.1371/journal.pone.0282017. eCollection 2023. PMID 36802389